SCHOTT Pharma (1SXP) investor relations material

Executive summary

• Q3 2026 revenue reached EUR 282 million, up 8.3% at constant currencies, with nine-month revenue at EUR 770 million, driven by high-value solutions (HVS) accounting for 59% of Q3 sales.

• EBITDA for Q3 was EUR 75 million (26.8% margin); nine-month EBITDA was EUR 205.3 million (26.7% margin), reflecting a slight year-over-year decrease.

• Growth was broad-based across the portfolio, not reliant on single customers or products, with strategic agreements and capacity expansions in the US, Hungary, and Switzerland.

• Profit for the period fell 9% to EUR 103.4 million, and EPS decreased to EUR 0.68 from EUR 0.75 year-over-year.

• Free cash flow surged 49% year-over-year, supported by working capital improvements and lower tax payments.

Financial highlights

• Q3 group revenues: EUR 281.8 million, up 8.3% at constant currencies and 10% reported; nine-month revenues: EUR 769.8 million, up 4.4% year-on-year.

• Q3 EBITDA: EUR 75 million (26.8% margin); nine-month EBITDA: EUR 205.3 million (26.7% margin), down 3.8% year-on-year.

• EBIT for nine months: EUR 139.7 million, down 10.4% year-on-year, mainly due to higher depreciation from growth investments.

• Net income for nine months: EUR 103.4 million, down 9% year-on-year; EPS EUR 0.68.

• Free cash flow for nine months: EUR 58.9 million; operating cash flow increased to EUR 140.7 million.

Outlook and guidance

• Full-year 2026 revenue growth guidance raised to 5%-6% at constant currencies; EBITDA margin guidance increased to 27%-28%.

• HVS revenue share expected to remain at 57% for the full year.

• Q4 revenue growth expected to accelerate, with DDS segment contributing strongly and a one-off revenue of around EUR 15 million from a new customer agreement, creating a headwind for 2027.

• CAPEX expected between EUR 140-160 million.

• Forecast assumes stable exchange rates and no major geopolitical or supply chain disruptions.